Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia

British Journal of Haematology

Volumn 96, Issue 3, 1997, Pages 617-619

  Bowen, A L ^a   Zomas, A ^a   Emmett, E ^a   Matutes, E ^a   Dyer, M J S ^a   Catovsky, D ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

B PLL; CAMPATH 1H; CLL; Fludarabine; MonoclonaI antibody

Indexed keywords

ALEMTUZUMAB; FLUDARABINE; GANCICLOVIR; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, B-CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, PROLYMPHOCYTIC; MALE; RECURRENCE; VIDARABINE;

EID: 0031027623     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.d01-2061.x     Document Type: Article

References (9)

1. Catovsky, D. & Murphy, R.L.W. (1995) Key issues in the treatment of chronic lymphocytic leukaemia. European Journal of Cancer, 31A, 2146-2154.
2. Dyer, M.J.S., Hale, G., Hayhoe, F.G.J. & Waldmann, H. (1989) Effects of CAMPATH-1H antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood, 73, 1431-1439.
3. Dyer, M.J.S., Hale, G., Marcus, R. & Waldmann, H. (1990) Remission induction in patients with lymphoid malignancies using unconjugated CAMPATH-1H monoclonal antibodies. Leukaemia and Lymphoma, 2, 179-193.
4. Hale, G., Dyer, M.J.S., Clark, M.R., Phillips, J.M., Marcus, R., Riechmann, L., Winter, G. & Waldmann, H. (1988) Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody, CAMPATH-1H. Lancet, ii, 1395-1401.
5. Hale, G. & Waldmann, H. (1994) Control of graft-versus-host disease and graft rejection by T-cell depletion of donor and recipient with CAMPATH-1 antibodies: results of matched sibling transplantation for malignant disease. Bone Marrow Transplantation, 13, 597-611.
6. Isaacs, J.D., Watts, R.A., Hazleman, B.L., Hale, G., Keogan, M.T., Cobbold, S.P. & Waldmann, H. (1992) Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet, 340, 48-52.
7. Mackay, H., Dyer, M.J.S., Kelsey, S.M., Emmett, E., Matutes, E., Hare, G., Wardmann, H., Newland, A.C. & Catovsky, D. (1986) In vivo 'purging' of residual disease in CLL with CAMPATH-1H. British Journal of Haematology, 93, (Suppl. 1), 291.
8. Osterberg, A., Passas, A.S., Anagnostopoulos, A., Dyer, M.J.S., Catovsky, D. & Mellstedt, H. (1996) Humanized CD52 monoclonal antibody CAMPATH-1H as first-line treatment in chronic lymphocytic leukaemia. British Journal of Haematology, 93, 152-153.
9. Riechmann, L., Clark, M.R., Waldmann, H. & Winter, G. (1988) Reshaping human antibodies for therapy. Nature, 332, 323-327.